Completion Date

Spring 2020

Document Type


Degree Name

Master of Science (MS)

Program or Discipline Name

Healthcare Informatics

First Advisor

Glenn Mitchell


Chronic migraine (CM) is characterized by the International Headache Society classification (ICHD-3) as headache that occurs for greater than or equal to 15 days a month, lasting 4 or more hours. For chronic migraine patients, the goal with prophylactic treatment is to prevent future attacks and reduce the migraine frequency and severity. OnabotulinumtoxinA is the most universally accepted medication for the treatment of chronic migraine; and if successful, reduces migraine frequency up to 50%. The goal of CGRP (Calcitonin-gene-related peptide) antagonists is to reduce the frequency of chronic migraines by targeting the CGRP protein that is elevated during a migraine attack. The aim of this study is to further explore the effectiveness of combining CGRP antagonists and Botox for the treatment of chronic migraine. We will analyze data to confirm or deny that migraine frequency is further reduced with the use of both medications.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.